Developing treatments for chronic diseases
 
family

We Develop Treatments For Chronic Diseases

TheraVasc, Inc. is a privately held, Ohio Based pharmaceutical company which is developing treatments for various chronic medical diseases using an oral formulation of sodium nitrite. Initial studies were done on patients with poor blood flow to the extremities, such as those suffering from peripheral artery disease (PAD).  In the U.S., 16 - 19 million people suffer from PAD but no effective treatments are currently available.
Learn more about us
family

TV1001SR is Being Developed to Treat Diabetic Neuropathy

We are developing a new drug, TV1001SR, to aid in the treatment of pain associated with diabetic neuropathy. With the incidence of diabetes steadily increasing and more people suffering from the symptoms of diabetic neuropathy, our research and development of this new drug may help reduce pain.
Learn more TV1001SR and Diabetic Neuropathy
family

TV1001SR and the Treatment of Peripheral Artery Disease (PAD)

Peripheral artery disease (PAD) is a chronic disorder associated with reduced blood flow to the lower extremities affecting between 12-14 million people in the U.S. We are developing TV1001SR to help in the prevention and treatment of PAD in an effort to combat the affects of this disease.
Learn more about TV1001SR and PAD
family

Theravasc in the News

Over the past several years, Theravasc has appeared in the news multiple times as we continue to work on the development of our new drug, TV1001SR. See press releases and news articles about us and the development of our new drug.
See Press Releases & News Articles

Dr. Amol Soin Is Interviewed About Our New Diabetic Pain Drug On Local Dayton TV

home-icon-newsRECENT NEWS